Skip to main navigation
Oculis Logo Oculis Logo Oculis Logo Oculis Logo Oculis Logo
  • COMPANY
    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us
  • SCIENCE
    • OPTIREACH Technology
    • Antibody Fragment Technology
    • NEUROPROTECTIVE APPROACH FOR EYE DISEASES
    • Publications
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 ACUTE OPTIC NEURITIS
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources
  • COMPANY
    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us
  • SCIENCE
    • OPTIREACH Technology
    • Antibody Fragment Technology
    • NEUROPROTECTIVE APPROACH FOR EYE DISEASES
    • Publications
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 ACUTE OPTIC NEURITIS
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources

News Releases


    Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
    March 22, 2023
    Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
    Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
    March 16, 2023
    Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
    Oculis to Present at BioCapital Europe
    March 9, 2023
    Oculis to Present at BioCapital Europe
    img
    March 3, 2023
    Oculis Announces US Public Listing on NASDAQ
    Glaucoma 360
    January 31, 2023
    Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum
    Eye drop
    January 5, 2023
    Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME)
Contact us

Oculis Holding AG
Bahnofstrasse 7
6300 Zug
Switzerland

+41 58 810 0182

 

info@oculis.com

Oculis SA
EPFL Innovation Park – Building D
Route J-D. Colladon
1015 Lausanne – Switzerland

+41 21 711 3970

Copyright © 2023 Oculis.

 





    © Oculis – Privacy Policy Terms of Use Cookie Policy

    © L’autreagence 2019 – 2022